Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
25 avr. 2024 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19 avr. 2024 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
15 avr. 2024 07h00 HE
|
Ultragenyx Pharmaceutical Inc.
Expansion Cohorts showed rapid, clinically meaningful improvement across multiple domains; improvements consistent or exceeding Dose-escalation Cohorts data at Day 170 Additional long-term data in...
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
12 avr. 2024 16h22 HE
|
Ultragenyx Pharmaceutical Inc.
Conference call now scheduled for Monday, April 15 at 8:00 a.m. ET Updated registration link below NOVATO, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)...
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
12 avr. 2024 08h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that preclinical and clinical data, including new clinical efficacy and safety data...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
22 mars 2024 16h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx to Participate at Investor Conferences in March
27 févr. 2024 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
44th Annual Cowen Healthcare Conference on March 4 Leerink Partners Global Biopharma Conference on March 12 Barclays 26th Annual Global Healthcare Conference on March 13 NOVATO, Calif., Feb. 27,...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
23 févr. 2024 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
15 févr. 2024 16h01 HE
|
Ultragenyx Pharmaceutical Inc.
2023 Total Revenue of $434 million, Crysvita® revenue of $328 million and Dojolvi® revenue of $71 million 2024 Financial Guidance: Total Revenue between $500 million and $530 million, Crysvita...
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
08 févr. 2024 16h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...